Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780

Pharmacology

Volumn 86, Issue 1, 2010, Pages 58-64

  Meyer, Matthias R ^a,b   Baretella, Oliver ^a   Prossnitz, Eric R ^c   Barton, Matthias ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Atherosclerosis; Coronary artery disease; Estrogen; Faslodex; Fulvestrant; Myocardial infarction; Vasodilation

Indexed keywords

ENDOTHELIN 1; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; G 1; G PROTEIN COUPLED RECEPTOR 30; HORMONE RECEPTOR BLOCKING AGENT; PROSTAGLANDIN F2 ALPHA; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; CORONARY ARTERY; EPICARDIUM; NONHUMAN; PRIORITY JOURNAL; SWINE; VASOCONSTRICTION;

ANIMALS; CORONARY VESSELS; CYCLOPENTANES; ENDOTHELIN-1; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PERICARDIUM; QUINOLINES; RECEPTORS, G-PROTEIN-COUPLED; SEROTONIN; SWINE; VASODILATION;

EID: 77954544185     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315497     Document Type: Article

References (44)

1. Fox B, James K, Morgan B, Seed A: Distribution of fatty and fibrous plaques in young human coronary arteries. Atherosclerosis 1982; 41: 337-347.
2. Yusuf S, Reddy S, Ounpuu S, Anand S: Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001; 104: 2746-2753.
3. Meyer MR, Haas E, Barton M: Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling. Hypertension 2006; 47: 1019-1026.
4. White RE: Estrogen and vascular function. Vascul Pharmacol 2002; 38: 73-80.
5. Mügge A, Riedel M, Barton M, Kuhn M, Lichtlen PR: Endothelium independent relaxation of human coronary arteries by 17 beta-oestradiol in vitro. Cardiovasc Res 1993; 27: 1939-1942.
6. Traupe T, Stettler CD, Li H, Haas E, Bhattacharya I, Minotti R, Barton M: Distinct roles of estrogen receptors alpha and beta mediating acute vasodilation of epicardial coronary arteries. Hypertension 2007; 49: 1364-1370.
7. Mügge A, Barton M, Fieguth HG, Riedel M: Contractile responses to histamine, serotonin, and angiotensin II are impaired by 17 beta-estradiol in human internal mammary arteries in vitro. Pharmacology 1997; 54: 162-168.
8. Sudhir K, Ko E, Zellner C, Wong HE, Hutchison SJ, Chou TM, Chatterjee K: Physiological concentrations of estradiol attenuate endothelin 1-induced coronary vasoconstriction in vivo. Circulation 1997; 96: 3626-3632.
9. Teoh H, Quan A, Leung SW, Man RY: Differential effects of 17beta-estradiol and testosterone on the contractile responses of porcine coronary arteries. Br J Pharmacol 2000; 129: 1301-1308.
10. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr: Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 2000; 14: 1649-1660.
11. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER: A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005; 307: 1625-1630.
12. Thomas P, Pang Y, Filardo EJ, Dong J: Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005; 146: 624-632.
13. Haas E, Meyer MR, Schurr U, Bhattacharya I, Minotti R, Nguyen HH, Heigl A, Lachat M, Genoni M, Barton M: Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension 2007; 49: 1358-1363.
14. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, Sklar LA, Oprea TI, Prossnitz ER: Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2006; 2: 207-212.
15. Haas E, Bhattacharya I, Brailoiu E, Damjanovic M, Brailoiu GC, Gao X, Mueller- Guerre L, Marjon NA, Gut A, Minotti R, Meyer MR, Amann K, Ammann E, Perez- Dominguez A, Genoni M, Clegg DJ, Dun NJ, Resta TC, Prossnitz ER, Barton M: Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ Res 2009; 104: 288-291.
16. Lindsey SH, Cohen JA, Brosnihan KB, Gallagher PE, Chappell MC: Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology 2009; 150: 3753-3758.
17. Broughton BR, Miller AA, Sobey CG: Endothelium- dependent relaxation by G proteincoupled receptor 30 agonists in rat carotid arteries. Am J Physiol Heart Circ Physiol 2010; 298:H1055-H1061.
18. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 1991; 51: 3867-3873.
19. Howell A, Osborne CK, Morris C, Wakeling AE: ICI 182,780 (Faslodex): development of a novel, 'pure' antiestrogen. Cancer 2000; 89: 817-825.
20. Vergote I, Abram P: Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. Ann Oncol 2006; 17: 200-204.
21. Brandes RP, Barton M, Philippens KM, Schweitzer G, Mügge A: Endothelial-derived superoxide anions in pig coronary arteries: evidence from lucigenin chemiluminescence and histochemical techniques. J Physiol 1997; 500: 331-342.
22. Leung HS, Yung LM, Leung FP, Yao X, Chen ZY, Ko WH, Laher I, Huang Y: Tamoxifen dilates porcine coronary arteries: roles for nitric oxide and ouabain-sensitive mechanisms. Br J Pharmacol 2006; 149: 703-711.
23. Tummala S, Hill BJ: The enhanced endothelin- 1-induced contraction in cultured coronary arteries from mature female pigs is not antagonized by 17beta-estradiol. Vascul Pharmacol 2007; 46: 346-352.
24. Fuster V, Ip JH, Badimon L, Badimon JJ, Stein B, Chesebro JH: Importance of experimental models for the development of clinical trials on thromboatherosclerosis. Circulation 1991; 83(Suppl 6):IV15-IV25.
25. DeLean A, Munson PJ, Rodbard D: Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 1978; 235:E97-E102.
26. Takada Y, Kato C, Kondo S, Korenaga R, Ando J: Cloning of cDNAs encoding G protein- coupled receptor expressed in human endothelial cells exposed to fluid shear stress. Biochem Biophys Res Commun 1997; 240: 737-741.
27. Mercier I, Mader S, Calderone A: Tamoxifen and ICI 182,780 negatively influenced cardiac cell growth via an estrogen receptorindependent mechanism. Cardiovasc Res 2003; 59: 883-892.
28. Ullrich ND, Krust A, Collins P, MacLeod KT: Genomic deletion of estrogen receptors ERalpha and ERbeta does not alter estrogenmediated inhibition of Ca 2+ influx and contraction in murine cardiomyocytes. Am J Physiol Heart Circ Physiol 2008; 294:H2421-H2427.
29. Teoh H, Leung SW, Man RY: Short-term exposure to physiological levels of 17 beta-estradiol enhances endothelium-independent relaxation in porcine coronary artery. Cardiovasc Res 1999; 42: 224-231.
30. Sudhir K, Chou TM, Mullen WL, Hausmann D, Collins P, Yock PG, Chatterjee K: Mechanisms of estrogen-induced vasodilation: in vivo studies in canine coronary conductance and resistance arteries. J Am Coll Cardiol 1995; 26: 807-814.
31. Shaw L, Taggart MJ, Austin C: Mechanisms of 17 beta-oestradiol induced vasodilatation in isolated pressurized rat small arteries. Br J Pharmacol 2000; 129: 555-565.
32. Bracamonte MP, Jayachandran M, Rud KS, Miller VM: Acute effects of 17beta-estradiol on femoral veins from adult gonadally intact and ovariectomized female pigs. Am J Physiol Heart Circ Physiol 2002; 283:H2389-H2396.
33. Scott PA, Tremblay A, Brochu M, St-Louis J: Vasorelaxant action of 17-estradiol in rat uterine arteries: role of nitric oxide synthases and estrogen receptors. Am J Physiol Heart Circ Physiol 2007; 293:H3713-H3719.
34. Bucci M, Roviezzo F, Cicala C, Pinto A, Cirino G: 17-beta-oestradiol- induced vasorelaxation in vitro is mediated by eNOS through hsp90 and akt/pkb dependent mechanism. Br J Pharmacol 2002; 135: 1695-1700.
35. Rubanyi GM, Freay AD, Kauser K, Sukovich D, Burton G, Lubahn DB, Couse JF, Curtis SW, Korach KS: Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta. Gender difference and effect of estrogen receptor gene disruption. J Clin Invest 1997; 99: 2429-2437.
36. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW: Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999; 103: 401-406.
37. Luksha L, Poston L, Gustafsson JA, Hultenby K, Kublickiene K: The oestrogen receptor beta contributes to sex related differences in endothelial function of murine small arteries via EDHF. J Physiol 2006; 577: 945-955.
38. Figtree GA, Webb CM, Collins P: Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor- dependent mechanism. J Pharmacol Exp Ther 2000; 295: 519-523.
39. Miller AP, Xing D, Feng W, Fintel M, Chen YF, Oparil S: Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries. Menopause 2007; 14: 251-260.
40. Deschamps AM, Murphy E: Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol 2009; 297:H1806-H1813.
41. Bopassa JC, Eghbali M, Toro L, Stefani E: A novel estrogen receptor GPER inhibits mitochondria permeability transition pore opening and protects the heart against ischemiareperfusion injury. Am J Physiol Heart Circ Physiol 2010; 298:H16-H23.
42. Collins P, Mosca L, Geiger MJ, Grady D, Kornitzer M, Amewou-Atisso MG, Effron MB, Dowsett SA, Barrett-Connor E, Wenger NK: Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation 2009; 119: 922-930.
43. Cummings SR, Ensrud K, Delmas PD, La Croix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R: Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010; 362: 686-696.
44. Filice E, Recchia AG, Pellegrino D, Angelone T, Maggiolini M, Cerra MC: A new membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 17beta-estradiol in the male rat. J Physiol Pharmacol 2009; 60: 3-10.